This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Efficacy/advantages

Authoring team

  • efficacy - with a failure rate of 1 in 1000, injectable hormonal contraception is more effective than use of the combined pill and female sterilisation (1 in 200 failure) (1)
    • when administered at the recommended dosing interval the failure rate of progestogen-only injectable contraception is approximately 0.2% in the first year of use. With typical use the failure rate is approximately 6% (2)
  • ease and convenience of use
  • use can be kept secret
  • reduced menstrual loss
  • independent of GIT function
  • independent of small intestine
  • not affected by antibiotics
  • avoids pass through the liver
  • fewer metabolic effects
  • can be used when oestrogens contraindicated
  • stimulates erythropoiesis - reduces crises in homozygous sickle cell disease
  • probable reduction in menstrual disorders and gynaecological disease as for combined oral contraceptive - exception of irregular bleeding - but amenorrhoea generally supervenes with regular use
  • reduced incidence of pelvic inflammatory disease

Reference:

  • 1) Prescriber (2001), 12 (5), 83-95.
  • 2) FSRH (December 2014). Progestogen-only injection contraception.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.